2025
Consensus guideline for the management of patients with appendiceal tumors, part 1: Appendiceal tumors without peritoneal involvement
Godfrey E, Mahoney F, Bansal V, Su D, Hanna D, Lopez‐Ramirez F, Baron E, Turaga K, Benson A, Cusack J, Winer J, Gunderson C, Misdraji J, Shah R, Magge D, Solsky I, Eng C, Eng O, Shergill A, Shen J, Foote M, Group P. Consensus guideline for the management of patients with appendiceal tumors, part 1: Appendiceal tumors without peritoneal involvement. Cancer 2025, 131: e35867. PMID: 40558045, DOI: 10.1002/cncr.35867.Peer-Reviewed Original ResearchConceptsAppendiceal tumorsPeritoneal involvementConsensus guidelinesHeterogeneous group of tumorsSystemic therapy recommendationsGroup of tumorsManagement of patientsAppendiceal malignancyAppendiceal adenocarcinomaIntraperitoneal chemotherapyMucinous neoplasmsMargin statusModified Delphi consensusPathological findingsClinical dataColorectal cancerPathological classificationPathway blockTherapy recommendationsTumorConsensus recommendationsObservational studyTherapy conceptsHeterogeneous groupStandard careConsensus guideline for the management of patients with appendiceal tumors, part 2: Appendiceal tumors with peritoneal involvement
Godfrey E, Mahoney F, Bansal V, Su D, Hanna D, Lopez‐Ramirez F, Baron E, Turaga K, Benson A, Setia N, Winer J, Gunderson C, Shah R, Magge D, Solsky I, Eng C, Eng O, Shergill A, Shen J, Misdraji J, Foote M, Luo W, Group P. Consensus guideline for the management of patients with appendiceal tumors, part 2: Appendiceal tumors with peritoneal involvement. Cancer 2025, 131: e35874. PMID: 40558065, DOI: 10.1002/cncr.35874.Peer-Reviewed Original ResearchConceptsManagement of appendiceal tumoursAppendiceal tumorsPeritoneal involvementConsensus guidelinesTiming of systemic chemotherapyDelphi consensusHeterogeneous group of tumorsHigh-grade diseaseGroup of tumorsManagement of patientsModified Delphi consensusAppendiceal malignancySystemic chemotherapyUnresectable diseasePeritoneal diseaseSystemic therapySurgical candidatesMost patientsNon-neuroendocrineSurveillance protocolsStandard careColorectal cancerPathological classificationPathway blockConsensus recommendationsConsensus Guideline for the Management of Patients with Appendiceal Tumors, Part 1: Appendiceal Tumors Without Peritoneal Involvement
Godfrey E, Mahoney F, Bansal V, Su D, Hanna D, Lopez-Ramirez F, Baron E, Turaga K, Benson A, Cusack J, Winer J, Gunderson C, Misdraji J, Shah R, Magge D, Solsky I, Eng C, Eng O, Shergill A, Shen J, Foote M. Consensus Guideline for the Management of Patients with Appendiceal Tumors, Part 1: Appendiceal Tumors Without Peritoneal Involvement. Annals Of Surgical Oncology 2025, 1-34. PMID: 40560498, DOI: 10.1245/s10434-025-17359-w.Peer-Reviewed Original ResearchAppendiceal tumorsPeritoneal involvementConsensus guidelinesHeterogeneous group of tumorsSystemic therapy recommendationsGroup of tumorsManagement of patientsAppendiceal malignancyAppendiceal adenocarcinomaIntraperitoneal chemotherapyMucinous neoplasmsMargin statusModified Delphi consensusPathological findingsClinical dataPathological classificationColorectal cancerPathway blockTherapy recommendationsTumorConsensus recommendationsObservational studyTherapy conceptsHeterogeneous groupStandard careConsensus Guideline for the Management of Patients with Appendiceal Tumors, Part 2: Appendiceal Tumors with Peritoneal Involvement
Godfrey E, Mahoney F, Bansal V, Su D, Hanna D, Lopez-Ramirez F, Baron E, Turaga K, Benson A, Setia N, Winer J, Gunderson C, Shah R, Magge D, Solsky I, Eng C, Eng O, Shergill A, Shen J, Misdraji J, Foote M, Luo W. Consensus Guideline for the Management of Patients with Appendiceal Tumors, Part 2: Appendiceal Tumors with Peritoneal Involvement. Annals Of Surgical Oncology 2025, 1-28. PMID: 40560501, DOI: 10.1245/s10434-025-17364-z.Peer-Reviewed Original ResearchManagement of appendiceal tumoursAppendiceal tumorsPeritoneal involvementConsensus guidelinesTiming of systemic chemotherapyHeterogeneous group of tumorsHigh-grade diseaseGroup of tumorsManagement of patientsDelphi consensusAppendiceal malignancySystemic chemotherapyUnresectable diseasePeritoneal diseaseSystemic therapySurgical candidatesModified Delphi consensusMost patientsNon-neuroendocrineSurveillance protocolsColorectal cancerPathological classificationPathway blockConsensus recommendationsTumorConsensus guideline for the management of colorectal cancer with peritoneal metastases
Schultz K, Bansal V, Wach M, Bhutiani N, Godley F, Wang J, Waheed M, Buchheit J, Papai E, Campbell S, Schleimer L, Su D, Turaga K, Gunderson C, White M, Uppal A, Raghav K, Labow D, Sarpel U, Shergill A, Shen J, Eng C, Foote M, Baumgartner J, Group P. Consensus guideline for the management of colorectal cancer with peritoneal metastases. Cancer 2025, 131: e35869. PMID: 40558054, DOI: 10.1002/cncr.35869.Peer-Reviewed Original ResearchConceptsManagement of colorectal cancerCRC-PMColorectal cancerPeritoneal metastasisConsensus guidelinesPeritoneal surface malignancy centersCirculating tumor DNA testingUpfront cytoreductive surgerySite of metastasisProspective multicenter trialOptimal treatment strategyAssess agreement levelsLevel of evidenceOverall level of evidenceClinical management pathwaysModified Delphi techniqueCytoreductive surgerySystemic therapyMulticenter trialRisk stratificationTreatment strategiesPathway blockWeak recommendationPathological featuresMetastasisConsensus Guideline for the Management of Colorectal Cancer with Peritoneal Metastases
Schultz K, Bansal V, Wach M, Bhutiani N, Godley F, Waheed M, Buchheit J, Papai E, Campbell S, Schleimer L, Su D, Turaga K, Gunderson C, White M, Uppal A, Raghav K, Labow D, Sarpel U, Shergill A, Shen J, Eng C, Foote M, Baumgartner J. Consensus Guideline for the Management of Colorectal Cancer with Peritoneal Metastases. Annals Of Surgical Oncology 2025, 1-23. PMID: 40560497, DOI: 10.1245/s10434-025-17363-0.Peer-Reviewed Original ResearchManagement of colorectal cancerPeritoneal surface malignanciesCirculating tumor DNACRC-PMColorectal cancerPeritoneal metastasisConsensus guidelinesUpfront cytoreductive surgerySite of metastasisProspective multicenter trialOptimal treatment strategyAssess agreement levelsModified Delphi techniqueResultsThe overall levelClinical management pathwaysBackgroundThe peritoneumCytoreductive surgerySurface malignanciesSystemic therapyTumor DNAMulticenter trialRisk stratificationTreatment strategiesPathway blockWeak recommendationClinicopathologic Features of Untreated Colorectal Cancer with Acellular Mucin-Only Lymph Nodes
Luo W, Hu S, Riahi I, Wang H, Shaker N, Abukhiran I, Wang T, Polydorides A, Akinsanya A, González I, Hagen C, Graham R, Lisovsky M, Longacre T, Challa B, Chen W, Harter D, Beech C, Najibi M, Cao W, Lee M, Lagana S, Liao X, Setia N, Westbrook L, Chandan V, Choi W, Ding X, Gonzalez R, Gopal P, Lee H, Navale P, Liu X, Panarelli N, Yang Z, Drage M, Song Z, Li F, Nagtegaal I, Zhang X. Clinicopathologic Features of Untreated Colorectal Cancer with Acellular Mucin-Only Lymph Nodes. Modern Pathology 2025, 38: 100811. PMID: 40513988, DOI: 10.1016/j.modpat.2025.100811.Peer-Reviewed Original ResearchUntreated colorectal cancerLymph nodesAcellular mucinColorectal cancerStudy groupClinicopathological featuresCRC casesFrequency of lymphovascular invasionPractice patternsCRC-related deathsControl groupTreat colorectal cancerPN0 groupLymphovascular invasionLocal recurrenceDistant metastasisPN1 groupMucinous featuresPN stageRight colonPN0Dutch nationwide pathology databankPathology DatabankPN1MetastasisNeuronal ALKAL2 and its ALK receptor contribute to the development of colitis-associated colorectal cancer
Delanne-Cuménal M, Defaye M, Delanne-Cuménal A, Ahmed M, Ho V, Abdullah N, Alhassoun M, Svendsen K, Mager L, Schlessinger J, Hirota S, Altier C. Neuronal ALKAL2 and its ALK receptor contribute to the development of colitis-associated colorectal cancer. Proceedings Of The National Academy Of Sciences Of The United States Of America 2025, 122: e2500632122. PMID: 40493183, PMCID: PMC12184428, DOI: 10.1073/pnas.2500632122.Peer-Reviewed Original ResearchConceptsColitis-associated colorectal cancerAnaplastic lymphoma kinaseColorectal cancerAnaplastic lymphoma kinase activityColitis-associated colorectal cancer progressionAnaplastic lymphoma kinase receptorTRPV1+ nociceptorsDevelopment of colitis-associated colorectal cancerMouse colonic organoidsALK signalingInflammatory painTumor burdenTreatment resistanceSensory neuronsTumor growthColonic organoidsALKAL2Colonic mucosaOverall inflammationCancer progressionCancerIn vivoTRPV1NeuronsInflammationIdentification of differential epigenetic landscapes in subtypes of appendiceal cancer.
Ladel L, Tan W, Sailo B, Das P, Tyagi A, Nalbantoglu I, Sharma A, Ahuja N. Identification of differential epigenetic landscapes in subtypes of appendiceal cancer. Journal Of Clinical Oncology 2025, 43: 4199-4199. DOI: 10.1200/jco.2025.43.16_suppl.4199.Peer-Reviewed Original ResearchDifferentially methylated regionsAppendiceal cancerAdvanced neoplasiaColorectal cancerCpG islandsAppendiceal neoplasmsNormal tissuesMalignant subtypeGenomic dataLow-grade appendiceal mucinous neoplasmEpigenetic landscapeHeterogeneous group of malignanciesPromoter regionAnalysis of CpG islandsAppendiceal mucinous neoplasmGroup of malignanciesNon-neoplastic controlsEnzymatic methyl-seqHypermethylated CpG islandsSingle-base resolutionHypomethylated CpG islandsRare malignancyQ-value cutoffMucinous neoplasmsEpigenetic clusteringCancer genetics evaluation among individuals at risk for Lynch syndrome across all qualifying indications.
Singh V, Chen G, Sena A, Rafter T, Xicola R, Sharbatji M, Liu J, Brown Q, Brierley K, Healy C, Hughes M, Kashyap N, Llor X. Cancer genetics evaluation among individuals at risk for Lynch syndrome across all qualifying indications. Journal Of Clinical Oncology 2025, 43: 10616-10616. DOI: 10.1200/jco.2025.43.16_suppl.10616.Peer-Reviewed Original ResearchLynch syndromeInherited cancer syndromeFamily historyPersonal historyCancer syndromesFamily history of colorectal cancerColorectal cancerPersonal history of cancerFamily history of cancerYale New Haven Health SystemLS-related cancersGenetic testingLS-associated cancersCancer genetic evaluationAt-riskIdentification of at-risk individualsAt-risk individualsPathogenic variantsLS cancersComparison of categorical variablesIndividuals at-riskEO-CRCPearson chi-squareHealth systemDescriptive statisticsThe first-in-human phase 1/2 study of TSN1611, a highly selective KRAS G12D inhibitor, in patients with advanced solid tumors.
Fu S, Shen L, Lu S, Sommerhalder D, Liu T, Spira A, Li J, Yu Y, Li W, Li J, Song B, Dong C, Lai L, Ma S, Shang E, Zhong B, Zhang T. The first-in-human phase 1/2 study of TSN1611, a highly selective KRAS G12D inhibitor, in patients with advanced solid tumors. Journal Of Clinical Oncology 2025, 43: 3083-3083. DOI: 10.1200/jco.2025.43.16_suppl.3083.Peer-Reviewed Original ResearchMaximum tolerated doseNon-small cell lung cancer modelTreatment related adverse eventsPancreatic ductal carcinomaColorectal cancerSolid tumorsFirst-in-human phase 1/2 studyRecommended phase 2 doseTumor cells in vitroMedian prior linesPhase 1/2 studyPhase 1b/2 studyPhase 2 dosePhase 2 partRelated grade 3Dose-limiting toxicityAdvanced solid tumorsDose-escalation partEvaluated dose rangeNausea and diarrheaInhibited tumor growthLung cancer modelRelated adverse eventsStandard of careCells in vitroA Feasibility Study of Mass-Based Response Drug Screening to Guide Personalized Hyperthermic Intraperitoneal Chemotherapy for Appendiceal and Colorectal Adenocarcinoma with Peritoneal Metastasis
Bader J, Ospina A, Liu S, Reddy B, Gupta P, Tomlin R, Cecchini M, Sundar R, Turaga K. A Feasibility Study of Mass-Based Response Drug Screening to Guide Personalized Hyperthermic Intraperitoneal Chemotherapy for Appendiceal and Colorectal Adenocarcinoma with Peritoneal Metastasis. Annals Of Surgical Oncology 2025, 1-11. PMID: 40445508, DOI: 10.1245/s10434-025-17517-0.Peer-Reviewed Original ResearchHyperthermic intraperitoneal chemotherapyPeritoneal surface malignanciesStandard of careHIPEC regimensColorectal cancerAppendiceal cancerCytoreductive surgeryIntraperitoneal chemotherapyPeritoneal metastasisTumor susceptibilityClinical trialsStandard of care regimenOpen-label clinical trialColorectal peritoneal metastasesHigh-grade appendicealRegimens to patientsPatient standard of careChemotherapy combinationsDiagnostic laparoscopySurface malignanciesSingle-centerChemotherapy sensitivityBiopsy tissueBackgroundCurrent treatmentsColorectal adenocarcinomaIndole-3-lactic acid suppresses colorectal cancer via metabolic reprogramming
Zhou S, Wang K, Huang J, Xu Z, Yuan Q, Liu L, Wang Z, Miao J, Wang H, Wang T, Guan W, Ding C. Indole-3-lactic acid suppresses colorectal cancer via metabolic reprogramming. Gut Microbes 2025, 17: 2508949. PMID: 40409349, PMCID: PMC12118437, DOI: 10.1080/19490976.2025.2508949.Peer-Reviewed Original ResearchConceptsIndole-3-lactic acidColorectal cancer patientsColorectal cancerAryl hydrocarbon receptorDownregulated glucose metabolismPotential clinical therapeutic targetsAnti-apoptotic capabilityInfluence tumor progressionGut microbiota metabolismTumor cell proliferationMetagenomic sequencingPhosphorylation sitesXenograft mouse modelGut microbiotaClinical therapeutic targetMetabolic reprogrammingMicrobiota metabolismP-STAT3Tumor progressionTumor malignancyMouse modelTryptophan metabolismCancer cellsIn vitro experimentsCRC developmentMitochondrial gene SLC25A24 regulated anti-tumor immunity and inhibited the proliferation and metastasis of colorectal cancer by PKG1-dependent cGMP/PKG1 pathway
Gao Y, Peng Y, Zhou Y, Zhu J, Fu S, Chen Y, Cai C, Han Y, Shen H, Zeng S, Mao L, Xiao Z. Mitochondrial gene SLC25A24 regulated anti-tumor immunity and inhibited the proliferation and metastasis of colorectal cancer by PKG1-dependent cGMP/PKG1 pathway. International Immunopharmacology 2025, 157: 114664. PMID: 40334626, DOI: 10.1016/j.intimp.2025.114664.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsAnti-tumor immunityColorectal cancerResponse to immune checkpoint inhibitorsAssociated with worse overall survivalKaplan-Meier survival analysisProgression-free survivalTumor immune regulationMetastasis of colorectal cancerMitochondrial solute carriersMicrosatellite instabilityColorectal cancer cell linesColorectal cancer patientsCancer-related mortalityProliferation-related markersCheckpoint inhibitorsColorectal cancer progressionOverall survivalImmune infiltrationPotential therapeutic targetPrognostic markerUnfavorable prognosisColorectal cancer tissuesImmune regulationClinical cohortCost-effectiveness of Lynch syndrome screening in colorectal cancer: universal germline vs sequential screening
Ito S, Xicola R, Sra M, Potnis K, Singh V, Gershkovich P, Stites E, Gibson J, Krumholz H, Llor X, Goshua G. Cost-effectiveness of Lynch syndrome screening in colorectal cancer: universal germline vs sequential screening. Clinical Gastroenterology And Hepatology 2025 PMID: 40315972, DOI: 10.1016/j.cgh.2025.03.006.Peer-Reviewed Original ResearchLynch syndromeIncremental cost-effectiveness ratioGermline testingColorectal cancerProspective Lynch Syndrome DatabaseColorectal cancer probandsNational Cancer Institute's SurveillancePre-/post-interventionPreventing cancer incidenceLynch syndrome screeningEnd Results ProgramCost-effective interventionHealth system perspectiveCost-effectiveCancer incidenceQuality-adjusted life expectancyInstitute's SurveillanceResults ProgramProspective interventionStandard-of-careCost-effectiveness ratioLS testingCohort studyGenetic testingPrimary outcomeQKI-induced circ_0001766 inhibits colorectal cancer progression and rapamycin resistance by miR-1203/PPP1R3C/mTOR/Myc axis
Zhou Y, Gao Y, Peng Y, Cai C, Han Y, Chen Y, Deng G, Ouyang Y, Shen H, Zeng S, Du Y, Xiao Z. QKI-induced circ_0001766 inhibits colorectal cancer progression and rapamycin resistance by miR-1203/PPP1R3C/mTOR/Myc axis. Cell Death Discovery 2025, 11: 192. PMID: 40263288, PMCID: PMC12015279, DOI: 10.1038/s41420-025-02478-w.Peer-Reviewed Original ResearchCRC cell proliferationCircular RNAsCompetitive endogenous RNAColorectal cancer tissuesInhibited CRC cell proliferationColorectal cancer progressionRapamycin resistanceColorectal cancerEndogenous RNADrug resistancePhosphorylation of MycRNA-binding proteinsModulating CRC progressionRate of drug resistanceActivation of mTOR signalingCell proliferationAssociated with patient survivalPre-mRNACircRNAsQKI expressionMYC phosphorylationIntron 1MYC pathwayCRC progressionInduce apoptosisSex-specific effects of exogenous asparagine on colorectal tumor growth, 17β-estradiol levels, and aromatase
Aladelokun O, Benitez K, Wang Y, Jain A, Berardi D, Maroun G, Shen X, Roper J, Gibson J, Sumigray K, Khan S, Johnson C. Sex-specific effects of exogenous asparagine on colorectal tumor growth, 17β-estradiol levels, and aromatase. Pharmacological Research 2025, 215: 107736. PMID: 40228761, PMCID: PMC12100670, DOI: 10.1016/j.phrs.2025.107736.Peer-Reviewed Original ResearchTumor-specific survivalColorectal cancerTumor growthR2G2 miceIncreased serum estradiol levelsSerum estradiol levelsSub-populations of macrophagesAssociated with cancer prognosisSuppressed tumor growthColorectal tumor growthExogenous asparagineColorectal cancer developmentColorectal cancer cellsNegative feed-back effectEstradiol levelsGlutamate levelsSex-related differencesSex-specific effectsMale miceCancer prognosisAsparagine supplementationCancer progressionMiceDecreased numberTumorHMBOX1 reverses autophagy mediated 5-fluorouracil resistance through promoting HACE1-induced ubiquitination and degradation of ATG5 in colorectal cancer
Gao Y, Fu S, Peng Y, Zhou Y, Zhu J, Zhang X, Cai C, Han Y, Shen H, Zeng S. HMBOX1 reverses autophagy mediated 5-fluorouracil resistance through promoting HACE1-induced ubiquitination and degradation of ATG5 in colorectal cancer. Autophagy 2025, 21: 1556-1577. PMID: 40126194, DOI: 10.1080/15548627.2025.2477443.Peer-Reviewed Original ResearchColorectal cancer cellsColorectal cancerCancer cellsColorectal cancer tissuesColorectal cancer tissues of patientsLiquid chromatography-tandem mass spectrometryChromatography-tandem mass spectrometryFetal human colonProgression-free survivalClinical colorectal cancer tissuesFirst-line treatmentCell Counting Kit-8Cancer tissues of patientsPostoperative colorectal cancerCaspase 3Transmission electron microscopyCounting Kit-8Tissues of patientsMass spectrometryCleaved caspase 3Stable diseaseComplete responsePartial responseOverall survivalRegulation of chemoresistanceBenzene exposure and risk of colorectal cancer by anatomical subsite in the Norwegian offshore petroleum workers cohort
Babigumira R, Veierød M, Larsen I, Berge L, Shala N, Marjerrison N, Samuelsen S, Bråtveit M, Kirkeleit J, Nordby K, Hosgood H, Demers P, Vermeulen R, Kromhout H, Engel L, Nilsen T, Silverman D, Friesen M, Rothman N, Lan Q, Grimsrud T, Stenehjem J. Benzene exposure and risk of colorectal cancer by anatomical subsite in the Norwegian offshore petroleum workers cohort. Environmental Research 2025, 276: 121407. PMID: 40118315, DOI: 10.1016/j.envres.2025.121407.Peer-Reviewed Original ResearchRisk of colorectal cancerOffshore petroleum workersJob-exposure matrixHazard ratioColorectal cancerAnatomic subsiteColorectal cancer riskConfidence intervalsColorectal cancer casesEstimate hazard ratiosCase-cohort analysisPetroleum workersWork historyExposure-response associationsPositive exposure-response associationsBody mass indexRight-sided colon cancerPublic health implicationsPhysical activityBenzene exposureMeat intakeAlcohol intakeQuartile 4Mass indexCase cohortColorectal adenosquamous carcinoma: clinicopathologic analysis of two large cohorts and literature review confirm poor prognosis and reveal prognostic aspects
Gonzalez R, Horton R, Zhang X, Graham R, Longacre T, Mehrotra A, Allende D, McHugh K, Shia J, Westerhoff M, Srivastava A, Chen W, Vazzano J, Swanson P, Chatterjee D, Cheema H, Ma C, Mannan R, Chetty R, Nowak K, Serra S, Agostini‐Vulaj D, Kazemimood R, Henn P, Kakar S, Choi W, Adeyi O, Jenkins S, Nagtegaal I. Colorectal adenosquamous carcinoma: clinicopathologic analysis of two large cohorts and literature review confirm poor prognosis and reveal prognostic aspects. Histopathology 2025, 86: 1064-1081. PMID: 39887413, DOI: 10.1111/his.15412.Peer-Reviewed Original ResearchTumor-infiltrating lymphocytesAdenosquamous carcinomaColorectal adenosquamous carcinomaTumor buddingPoor prognosisMedian time to progressionMeta-analysis of cohortLow tumor buddingTime to progressionMale:female ratioReview of casesIndividual case seriesNodal metastasisRecurrent diseaseSquamous componentPatient ageRecurrence rateAcademic medical centreCase seriesImmunohistochemical featuresPrognostic aspectsClinicopathological analysisFemale ratioFollow-upColorectal cancer
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply